Abstract
Background and purpose
Methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Radiotherapy and OncologyReferences
- Cancer statistics 2007.CA Cancer J Clin. 2007; 57: 43-66
- Global cancer statistics 2002.CA Cancer J Clin. 2005; 55: 74-108
- Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.J Urol. 2003; 169: 517-523
- Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients.Urology. 2005; 6: 1245-1250
Scardino P. Prostate cancer. National comprehensive cancer network practice guidelines in oncology. [monograph on the Internet]. [cited 2006 Mar 1]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf.
- Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005; 366: 2087-2106
- The results of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer.Int J Radiat Oncol Biol Phys. 1996; 34: 535-541
- Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.Int J Radiat Oncol Biol Phys. 1997; 38: 731-736
- The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis.Int J Radiat Oncol Biol Phys. 1999; 45: 53-58
- Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.Urology. 1999; 54: 111-117
- Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.J Urol. 2000; 163: 1178-1182
- PSA based review of adjuvant and salvage radiation therapy vs observation in postoperative prostate cancer patients.Int J Cancer. 2000; 90: 29-36
- Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.Radiother Oncol. 2001; 59: 51-60
- Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?.Int J Radiat Oncol Biol Phys. 2002; 52: 674-680
- Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival.Am J Clin Oncol. 2002; 25: 1-8
- Postprostatectomy radiotherapy for high-risk prostate cancer.Urology. 2002; 59: 732-739
- Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.Int J Radiat Oncol Biol Phys. 2002; 53: 600-609
- Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients.Int J Radiat Oncol Biol. 2004; 59: 674-683
- Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy.Int J Radiat Oncol Biol Phys. 2004; 59: 329-340
- Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.Int J Radiat Oncol Biol Phys. 2005; 61: 714-724
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement.Lancet. 1999; 354: 1896-1900
Higgins J, Green S, editors. Approaches to summarising the validity of studies. Cochrane handbook for systematic reviews of interventions 4.2.5; Section 6.7. The Cochrane Library [monograph on the Internet]. Updated May 2005 [cited 2006 Mar 1]. Available from: http://www.cochrane.org/resources/handbook/hbook.htm.
- Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.Stat Med. 1998; 17: 2815-2834
- Measuring inconsistency in meta-analyses.BMJ. 2003; 327: 557-560
- Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).Lancet. 2005; 366: 572-578
- Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostrative cancer (PC)? (EORTC 22911) [abstract].Proc Am Soc Clin Oncol. 2004; 22: 383s
- Post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improves progression-free survival (PFS) in pT3N0 prostate cancer (PC) (EORTC 22911) [abstract].Int J Radiat Oncol Biol Phys. 2004; 60: S186
Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Rigatti P, De Reijke T, et al. Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? 2004 [cited 2008 Feb 21]. Available from: http://media.asco.org/asco/meetings_education/module/slides_only/frame.asp
- Quality assurance of the EORTC trial 22911 A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run.Radiother Oncol. 2002; 64: 65-73
- Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.J Clin Oncol. 2007; 25: 4178-4186
- Adjuvant radiotherapy for pathologically advanced prostate cancer. A randomized clinical trial.JAMA. 2006; 296: 2329-2335
- Adjuvant radiotherapy for pathologic T3 prostate cancer: results of a randomized, prospective clinical trial with metastasis-free survival endpoint [slide presentation].AUA. 2005;
- Adjuvant radiotherapy for pT3 prostate cancer. Results of a randomized, prospective clinical trial [abstract].J Urol. 2005; 173: A451-A452
- Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794) [abstract].Int J Radiat Oncol Biol Phys. 2005; 63: S1
- Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.J Clin Oncol. 2007; 25: 2225-2229
- Phase III results of adjuvant radiotherapy (RT) versus wait and see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/ AUO AP 09/95) [abstract].Proc Am Soc Clin Oncol. 2005; 23: 381s
- Phase III results of adjuvant radiotherapy versus wait and see in patients with pT3 prostate cancer following radical prostatectomy (ARO 96-02/AUO AP 09/95) [abstract].Int J Radiat Oncol Biol Phys. 2007; 69: S172
Wiegel T, Hinkelbein W, Bottke D, Willich N, Piechota H, Souchon R, et al. Adjuvant RT versus wait and see in patients with pT3 prostate cancer after radical prostatectomy – 5 year results [slide presentation]. 2007 [cited 2008 Feb 21]. Available from: http://media.asco.org/player/default.aspx
- RADICALS (radiotherapy and androgen deprivation in combination after local surgery).Clin Oncol. 2007; 19: 167-171
- A systematic overview of radiation therapy effects in prostate cancer.Acta Oncol. 2004; 43: 316-381
Wiegel T. Personal Communication. April 3, 2008.
- Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.J Clin Oncol. 2008; 26: 112-120
- Advanced prostate cancer and postoperative radiotherapy – author reply.JAMA. 2007; 297: 951
- Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.J Clin Oncol. 2007; 25: 2420-2425
- Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.J Clin Oncol. 2006; 24: 4448-4456
- Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy.J Urol. 2003; 170: 1841-1842
- Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group.Radiother Oncol. 2007; 84: 121-127
- Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy.Int J Radiat Oncol Biol Phys. 2007; 69: 1090-1099
- Radiotherapy for men with isolated increase in serum prostate specific after radical prostatectomy: the first 10 years.Int J Radiat Oncol Biol Phys. 2000; 48: 369-375
- Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911).Virchows Arch. 2006; 449: 428-434
- Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation?.Eur J Cancer. 2005; 41: 2662-2672